Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
14–50
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult and adolescent patients, 14-50 years of age
Diagnosis of fragile X syndrome with a confirmed fragile X mental retardation 1 (FMR1) full mutation and qualifying scores on the Aberrant Behavior Checklist (ABC) and CGI-S
Patients must agree to either remain completely abstinent or to use two effective contraceptive methods during and 3 weeks after the study
You may not be if
Previous treatment with another metabotropic glutamate (mGLU) receptor antagonist within 18 months or with RO4917523
Participation in a clinical trial involving an investigational (unapproved) drug within 3 months or 5 times the half-life (whichever is longer) before start of this study
Any uncontrolled, unstable clinically significant psychiatric condition other than fragile X syndrome
History of suicidal behavior
Clareo Health | A Study of RO4917523 in Patients With Fragile X Syndrome
